CervoMed is trading at $3.11, +6.28% now, as flat July PPI data reduced expectations for a September Federal Reserve rate hike.

  • Broader risk appetite strengthened following the inflation data.
  • No new company-specific announcement for August 14, 2026, was identified.
  • The move appears tied to macro sentiment rather than a company catalyst.